<!doctype html>
<html lang="en">
<head>
	<meta charset="UTF-8" />
	<title>Etilogy</title>
    <link href="../css/bootstrap.css"  rel="stylesheet" />
    <!-- <link href="../css/normalize.css"  rel="stylesheet" /> -->
    <link href="../css/style.css"  rel="stylesheet" />
</head>
<body>
<div class="main_wrapper" id="etilogypath"> 
	<header>
		<div class="container">
		</div>
	</header>
	<div class="bgsection bgCol">
		<div class="container">
			<div class="row">
				<div class="col-md-12 ">
					<h1>Etiology & Pathogenesis</h1>
				</div>
			</div>
		</div>
	</div>
	<div class="bgwhite">
	<div class="container">
		<div class="row">
			<div class="col-md-12">
				<h2 class="border_color">Etiology and the role of vasopressin in hypotonic hyponatremia</h2>
			     <p>Hypotonic hyponatremia has multiple etiologies <sup>1-3</sup></p>
			     <p>Etiologies can be categorized under the 3 main  <a href="#">volume statuses</a> hypovolemic hyponatremia, euvolemic hyponatremia. and hypervolemic hyponatremia. Laboratory data and a physical exam will help assess patients’ volume status. The volume status will help determine the etiology of the hyponatremia.<sup>1-3</sup>  </p>
					
			</div>
		</div>
	</div>
	</div>
	<div class="bgblue">
		<div class="container">
			<div class="row">
				<div class="col-md-12">
				   <h3>Etiologies of the 3 main classes of hypotonic hyponatremia<sup>1-3</sup> </h3>
				    <table class="table">
				    	<thead><tr>
				    		<th>
				    			Hypovolemic Hyponatremia
				    		</th>
				    		<th class="text-center">
				    		Euvolemic Hyponatremia
				    		</th>
				    		<th class="text-center">
				    	  Hypervolemic Hyponatremia
				    		</th>
				    	</tr>
				    </thead>
				    <tbody>
				    		<tr>
				    			<td>
				    				<ul class="table_ul">
				    				<li>Cerebral salt-wasting</li>
				    			    <li>Diuretic therapy</li>
				    			    <li>GI losses (diarrhea, vomiting)</li>
				    			    <li>Ketonuria</li>
				    			    <li>Mineralocorticoid deficiency</li>
				    			    <li> Osmotic diuresis</li>
				    			    <li>Third-spacing (burns, pancreatitis)</li>
				    		       </ul>
				    		   </td>
				    		
				    		<td>
				    			    <ul class="table_ul">
				    				<li>Exercise associated</li>
				    				<li>Glucorticoid deficiency</li>
				    				<li>Hypothyroidism</li>
				    				<li>Low solute intake</li>
				    				<li>NSIAD</li>
				    				<li>Primary polydipsia</li>
				    				<li>Reset osmostat</li>
				    				<li>SIADH</li>
				    			     </ul>
				    		</td>
				    		<td>
				    			<ul class="table_ul">
				    			<li>Acute/chronic renal failure</li>
				    			<li>Cirrhosis</li>
				    			<li>Heart failure</li>
				    			<li>Nephrotic syndrome </li>
				    			</ul>
				    		</td>
				    	    </tr>
				    	
				    		
				    		<!-- <td class="text-center"> &lt; 120<sup>2,7,8</sup></td> -->
				    
				    	</tbody>
				    	 
				    </table>
				    <p class="font_12">NSIAD: Nephrogenic Syndrome of Inappropriate Antidiuresis; </p>
				    	 <p class="font_12">SIADH: Syndrome of Inappropriate Antidiuretic Hormone.</p>
				</div>
			</div>
		</div>
	</div>
	
   <div class="bgwhite">
   	<div class="container">
   		<div class="row">
   			<div class="col-md-12">
   				<h3>Pathogenesis of hyponatremia and the role of vasopressin</h3>
   				<p>Hypotonic hyponatremia typically results from a disruption in the free water clearance from the kidneys, which is usually due to vasopressin release or renal failure.<sup>4</sup></p>
   				<p>Vasopressin, also known as arginine vasopressin (AVP) or antidiuretic hormone (ADH), leads to renal water reabsorption. Vasopressin is regulated by osmoreceptors and baroreceptors, and is released in response to<sup>4,5</sup>: </p>
   				<ul>
   					<li><span>Increased plasma osmolality</span></li>
   					<li><span>Decreased blood volume or pressure</span></li>
   				</ul>
   				<p>Vasopressin mechanism of action in renal water reabsorption<sup>5-7</sup>: </p>
   				<ul>
   					<li><span>Vasopressin binds to the G-protein–coupled vasopressin V2 receptor on the basolateral membrane of the renal collecting duct cells </span></li>
   					<li><span>G-protein–coupled signaling following vasopressin binding leads to activation of adenylyl cyclase causing an increase in intracellular cAMP</span></li>
   					<li><span>cAMP binds to protein kinase A (PKA) activating the catalytic subunits that are bound to the cytoplasmic vesicle containing aquaporin-2 (AQP2) channels</span></li>
   					 <li><span>Activation of PKA results in phosphorylation of the AQP2 channels</span></li>
   					 <li><span>Phosphorylation of the AQP2 channels results in the AQP2 channels translocating to the luminal membrane of the renal collecting duct cell</span></li>
   					 <li><span>Translocation of AQP2 channels to the luminal membrane of the collecting duct cell allows water to be reabsorbed from the collecting duct </span></li>
   					 <li><span>AQP2 channels are retrieved back into the cell by endocytosis when vasopressin is not bound to the V2 receptor </span></li>
   				</ul>
   			</div>
   		</div>
   	</div>
   </div>
    <div class="bgblue">
    	<div class="container">
    		<div class="row">
    			<div class="col-md-12">
    				<p class="text-center">Vasopressin V2-receptor activation</p>
    			     <div class="text-center">
    			     		<img  src="../images/vasporation.jpg" />
    			     </div>
    				<p class="font_12 ">V2R = V2-receptor; PKA=protein kinase A; AQWCV=aquaporin water channel-containing vesicles; </p>
    				<p class="font_12">AQ2=aquaporin 2; CD=collecting duct.</p>
    			</div>
    		</div>
    	</div>
    </div>
    
    <div class="bgskyblue">
    	<div class="container">
    		<div class="row">
    			<div class="col-md-12">
    				<h3 class="font_36">Vasopressin often plays a role in hyponatremia<sup>5,7-9</sup> </h3>
    				<p>Vasopressin secretion is suppressed once serum osmolality drops below normal; however, there are 2 instances in which vasopressin secretion will be sustained or even increased despite serum hypo-osmolality. These two cases are listed below<sup>5,7</sup>:  </p>
    				<h3><span class="badge">1</span>Hemodynamic or baroreceptor stimuli </h3>
    				<ul>
    					<li><span>Osmotic signals to suppress vasopressin secretion are overridden when the arterial baroreceptors sense a decrease in effective circulatory volume4,7,10 </span></li>
    					<li><span>Decreases in effective circulatory volume can be due to<sup>7,10</sup>: </span>
    						<ul>
    							<li>Decreased cardiac output (CO)</li>
    							<li>Plasma volume depletion</li>
    							<li>Systemic arterial vasodilation</li>
    						</ul>
    					</li>
    					<li><span>Diseases that cause a decrease in effective circulatory volume include<sup>5,10</sup>:</span>
    					  <ul>
    					  	<li>Cirrhosis (systemic vasodilation)</li>
    					  	<li>High-CO heart failure (systemic vasodilation)</li>
    					  	<li>Low-CO heart failure (decreased cardiac output)</li>
    					  	<li>Sepsis (systemic vasodilation)</li>
    					  </ul>	
    					</li>
    					<li><span>Sustained or increased vasopressin release as a result of decreased effective circulatory volume occurs by the following mechanisms<sup>5,10,11</sup>: </span>
    						
    						<ol>
    					 	<li>The decreased effective circulatory volume is sensed by the arterial baroreceptors in the carotid   sinus and aortic arch resulting in afferent signals to the brain</li>
    					 	<li>The afferent signals result in the release of vasopressin as well as stimulation of sympathetic   efferent pathways</li>
    					 	<li>Increased sympathetic stimulation may also lead to the release of vasopressin</li>
    					 	<li> Increased sympathetic stimulation can result in activation of the renin-angiotensin system (RAS), which can cause the release of vasopressin</li>
    					 </ol>
    					</li>
    					
    				</ul>
    				<h3><span class="badge">2</span>Dysregulation of cells that secrete vasopressin  </h3>
    				 <ul>
    				 	<li><span>Vasopressin release in this cause is not caused by osmotic or hemodynamic stimuli<sup>5,7,12</sup></span></li>
    				 	<li><span>Causes for vasopressin release include: </span>
    				 		<ul>
    				 			<li>Ectopic production of vasopressin by tumors<sup>7,12</sup></li>
    				 			<li> Stimulation vasopressin release by drugs<sup>7,12</sup></li>
    				 			<li>A lowered threshold for vasopressin release<sup>12</sup></li>
    				 			<li>Dysfunction of hypothalamus that results in persistent low-grade vasopressin secretion<sup>12</sup></li>
    				 		</ul>
    				 	</li>
    				 	<li><span>This occurs in hyponatremia caused by SIADH<sup>7</sup></span></li>
    				 </ul>
    			  <div class="padding_bottom bgimg ">
    					 <div class="col-md-3">
    						<h3>Sign Up for a Hyponatremia Updates Account</h3>
    					</div>
    					 <div class="col-md-9">
    					   <div class="row">
    					   
    					   		<p class="padding_40">With a Hyponatremia Updates account, you can have access to peer-reviewed publications and/or you can stay informed with email updates from Hyponatremia News.</p>
    					   	    <div class="col-md-3">
    					   	    	<button class="btn">SIGN UP NOW  </button>
    					   	    </div>
    					   	    <div class="col-md-9">
    					   	    <p class="padding_20">Already have an account? <a href="#">Log In</a> </p>
    					   	    </div>
    					 
    					   </div>
    					</div>  
    				</div>
    				<div class="row padding_bottom">
    					<div class="col-md-4">
    						<img  src="../images/music.jpg" />
    					</div>
    					<div class="col-md-8 bgblueS">
    					   <div class="">
    					   	<div class="col-md-9">
    					   		<h3>Prevalence of Hyponatremia and Diagnostic Considerations</h3>
    					   		<p>Listen to hospitalist Amir K. Jaffer, MD, speak about the epidemiology of hyponatremia and diagnostic considerations.</p>
    					   	</div>
    					   	<div class="col-md-3">
    					   		<button class="btn pull-right"> listen<br> now</button>
    					   	</div>
    					   </div>
    					</div>
    				</div>
    				
    							
    				<div class="row padding_bottom">
    					<div class="col-md-4">
    						<img  src="../images/buliding.jpg" />
    					</div>
    					<div class="col-md-8 bgblueS">
    					   <div class="">
    					   	<div class="col-md-9">
    					   		<h3>Epidemiologic Studies in Hyponatremia</h3>
    					   		<p class="padding_bottom">Learn more about the epidemiology of hyponatremia as well as other clinical topics in hyponatremia, by watching a presentation by nephrologist Tomas Berl, MD.</p>
    					   	</div>
    					   	<div class="col-md-3">
    					   		<button class="btn pull-right"> learn<br> more</button>
    					   		
    					   	</div>
    					   </div>
    					</div>
    				</div>
    			</div>
    		</div>
    	</div>
    </div>
    
    <div class="bgwhite">
    	<div class="container">
    		<div class="row">
    			 <div class="col-md-12">
    				<div class="clearfix"></div>
    				<div class="">
    					<h4 class="dash">References</h4>
    					<ol>
    						<li> Assadi F. Hyponatremia: a problem-solving approach to clinical cases. J Nephrol. 2012; 25(4):473-380. doi:10.5301/jn.5000060. </li>
    						<li> Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006;73(Suppl 3):S4-S12</li>
    						<li>Sra J, Repp AB. Hyponatremia. Hosp Med Clin. 2012;1:e199-e208. doi:10.1016/j.ehmc.2012.03.007.</li>
    						<li>Rudolph EH, Pendergraft WF, Lerma EV. Common electrolyte disorders: hyponatremia. Hosp Physician. 2009;48:23-32.</li>
    						<li>Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-S42. doi:10.1016/j.amjmed.2013.07.006.</li>
    						<li> Knoers NV. Hyperactive vasopressin receptors and disturbed water homeostasis. N Engl J Med.  2005; 352(18):1847-1850.</li>
    						<li>Rai A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vasopressin dysreguation, and vasopressin receptor antagonism. Am J Nephrol. 2006;26(6):579-589.</li>
    						<li>Anderson RJ, Chung HM, Kluge R, Schrier RW. Hyponatremia: a prospective analysis of its epidemiology and the pathogenic role of vasopressin. Ann Intern Med. 1985;102(2):164-168. </li>
    						<li>Arieff AI. Management of hyponatraemia. BMJ. 1993;307(6899):305-308.</li>
    						<li>Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol. 2007;18:2028-2031. doi: 10.1681/ASN/200611302.</li>
    						<li>Mann DL. Pathophysiology of heart failure. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:487-504.</li>
    						<li> Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol. 2010;162(Suppl1):S5-S12.</li>
    					</ol>
    				</div>
    		      </div>
    		</div>
    	</div>
    </div>

</div>
<script src="../js/jquery-2.1.3.js"></script>
<script src="../js/bootstrap.js"></script>
<script src="../js/skrollr.js"></script>
<script src="../js/enquire.js"></script>
<script src="../js/_main.js"></script>
<script src="../js/headerfixed.js"></script>
</body>
</body>
</html>